Monte Rosa Therapeutics Statistics
Total Valuation
GLUE has a market cap or net worth of $297.68 million. The enterprise value is $48.22 million.
| Market Cap | 297.68M |
| Enterprise Value | 48.22M |
Important Dates
The last earnings date was Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GLUE has 61.76 million shares outstanding. The number of shares has increased by 38.55% in one year.
| Current Share Class | 61.76M |
| Shares Outstanding | 61.76M |
| Shares Change (YoY) | +38.55% |
| Shares Change (QoQ) | -0.93% |
| Owned by Insiders (%) | 0.73% |
| Owned by Institutions (%) | 53.01% |
| Float | 30.30M |
Valuation Ratios
The trailing PE ratio is 16.38.
| PE Ratio | 16.38 |
| Forward PE | n/a |
| PS Ratio | 2.22 |
| Forward PS | 8.98 |
| PB Ratio | 1.11 |
| P/TBV Ratio | 1.11 |
| P/FCF Ratio | 12.48 |
| P/OCF Ratio | 10.74 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 2.07, with an EV/FCF ratio of 2.02.
| EV / Earnings | 2.00 |
| EV / Sales | 0.27 |
| EV / EBITDA | 2.07 |
| EV / EBIT | 3.22 |
| EV / FCF | 2.02 |
Financial Position
The company has a current ratio of 7.16, with a Debt / Equity ratio of 0.15.
| Current Ratio | 7.16 |
| Quick Ratio | 7.00 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 1.26 |
| Debt / FCF | 1.72 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 9.81% and return on invested capital (ROIC) is 3.23%.
| Return on Equity (ROE) | 9.81% |
| Return on Assets (ROA) | 2.66% |
| Return on Invested Capital (ROIC) | 3.23% |
| Return on Capital Employed (ROCE) | 4.71% |
| Revenue Per Employee | $1.33M |
| Profits Per Employee | $180,358 |
| Employee Count | 134 |
| Asset Turnover | 0.51 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GLUE has paid $4.26 million in taxes.
| Income Tax | 4.26M |
| Effective Tax Rate | 14.97% |
Stock Price Statistics
The stock price has decreased by -26.19% in the last 52 weeks. The beta is 1.42, so GLUE's price volatility has been higher than the market average.
| Beta (5Y) | 1.42 |
| 52-Week Price Change | -26.19% |
| 50-Day Moving Average | 4.93 |
| 200-Day Moving Average | 5.86 |
| Relative Strength Index (RSI) | 51.76 |
| Average Volume (20 Days) | 423,801 |
Short Selling Information
The latest short interest is 8.70 million, so 14.09% of the outstanding shares have been sold short.
| Short Interest | 8.70M |
| Short Previous Month | 8.92M |
| Short % of Shares Out | 14.09% |
| Short % of Float | 28.72% |
| Short Ratio (days to cover) | 20.00 |
Income Statement
In the last 12 months, GLUE had revenue of $177.99 million and earned $24.17 million in profits. Earnings per share was $0.29.
| Revenue | 177.99M |
| Gross Profit | 56.55M |
| Operating Income | 14.96M |
| Pretax Income | -129.93M |
| Net Income | 24.17M |
| EBITDA | 23.30M |
| EBIT | 14.96M |
| Earnings Per Share (EPS) | $0.29 |
Balance Sheet
The company has $290.59 million in cash and $41.13 million in debt, giving a net cash position of $249.46 million or $4.04 per share.
| Cash & Cash Equivalents | 290.59M |
| Total Debt | 41.13M |
| Net Cash | 249.46M |
| Net Cash Per Share | $4.04 |
| Equity (Book Value) | 268.08M |
| Book Value Per Share | 4.34 |
| Working Capital | 257.61M |
Cash Flow
In the last 12 months, operating cash flow was $27.72 million and capital expenditures -$3.86 million, giving a free cash flow of $23.85 million.
| Operating Cash Flow | 27.72M |
| Capital Expenditures | -3.86M |
| Free Cash Flow | 23.85M |
| FCF Per Share | $0.39 |
Margins
Gross margin is 31.77%, with operating and profit margins of 8.40% and 13.58%.
| Gross Margin | 31.77% |
| Operating Margin | 8.40% |
| Pretax Margin | 15.97% |
| Profit Margin | 13.58% |
| EBITDA Margin | 13.09% |
| EBIT Margin | 8.40% |
| FCF Margin | 13.40% |
Dividends & Yields
GLUE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.55% |
| Shareholder Yield | -38.55% |
| Earnings Yield | 8.12% |
| FCF Yield | 8.01% |
Analyst Forecast
The average price target for GLUE is $13.50, which is 180.08% higher than the current price. The consensus rating is "Buy".
| Price Target | $13.50 |
| Price Target Difference | 180.08% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | -0.82% |
| EPS Growth Forecast (5Y) | 7.43% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GLUE has an Altman Z-Score of 2.25 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.25 |
| Piotroski F-Score | 7 |